TY - JOUR
T1 - Analgesic effects of dexmedetomidine in vincristine-evoked painful neuropathic rats
AU - Park, Hue Jung
AU - Kim, Young Hoon
AU - Koh, Hyun Jung
AU - Park, Chul Soo
AU - Kang, Seung Hee
AU - Choi, Jong Ho
AU - Moon, Dong Eon
PY - 2012
Y1 - 2012
N2 - Dexmedetomidine, which is a selective α2-adrenoceptor agonist, was recently introduced into clinical practice for its analgesic properties. The purpose of this study was to evaluate the effects of dexmedetomidine in a vincristine-evoked neuropathic rat models. Sprague-Dawley rats were injected intraperitoneally with vincristine or saline (0.1 mg/kg/day) using a 5-day-on, 2-day-off schedule for 2 weeks. Saline and dexmedetomidine (12.5, 25, 50, and 100 μg/kg) were injected to rats developed allodynia 14 days after vincristine injection, respectively. We evaluated allodynia at before, 15, 30, 60, 90, 120, 180, and 240 min, and 24 hr after intraperitoneal drug (normal saline or dexmedetomidine) injection. Saline treatment did not show any differences for all the allodynia. Maximal paw withdrawal thresholds to mechanical stimuli were 3.0 ± 0.4, 9.1 ± 1.9, 13.0 ± 3.6, 16.6 ± 2.4, and 24.4 ± 1.6 g at saline, 12.5, 25, 50, and 100 μg/kg dexmedetomidine injection, respectively. Minimal withdrawal frequency to cold stimuli were 73.3 ± 4.2, 57.1 ± 6.8, 34.3 ± 5.7, 20.0 ± 6.2, and 14.3 ± 9.5 g at saline, 12.5, 25, 50, and 100 μg/kg dexmedetomidine injection, respectively. Dexmedetomidine shows a dose-dependent anti-allodynic effect on mechanical and cold stimuli in vincristine-evoked neuropathic rat models (P < 0.05).
AB - Dexmedetomidine, which is a selective α2-adrenoceptor agonist, was recently introduced into clinical practice for its analgesic properties. The purpose of this study was to evaluate the effects of dexmedetomidine in a vincristine-evoked neuropathic rat models. Sprague-Dawley rats were injected intraperitoneally with vincristine or saline (0.1 mg/kg/day) using a 5-day-on, 2-day-off schedule for 2 weeks. Saline and dexmedetomidine (12.5, 25, 50, and 100 μg/kg) were injected to rats developed allodynia 14 days after vincristine injection, respectively. We evaluated allodynia at before, 15, 30, 60, 90, 120, 180, and 240 min, and 24 hr after intraperitoneal drug (normal saline or dexmedetomidine) injection. Saline treatment did not show any differences for all the allodynia. Maximal paw withdrawal thresholds to mechanical stimuli were 3.0 ± 0.4, 9.1 ± 1.9, 13.0 ± 3.6, 16.6 ± 2.4, and 24.4 ± 1.6 g at saline, 12.5, 25, 50, and 100 μg/kg dexmedetomidine injection, respectively. Minimal withdrawal frequency to cold stimuli were 73.3 ± 4.2, 57.1 ± 6.8, 34.3 ± 5.7, 20.0 ± 6.2, and 14.3 ± 9.5 g at saline, 12.5, 25, 50, and 100 μg/kg dexmedetomidine injection, respectively. Dexmedetomidine shows a dose-dependent anti-allodynic effect on mechanical and cold stimuli in vincristine-evoked neuropathic rat models (P < 0.05).
KW - Dexmedetomidine
KW - Neuropathy
KW - Pain
KW - Vincristine
UR - http://www.scopus.com/inward/record.url?scp=84872542959&partnerID=8YFLogxK
U2 - 10.3346/jkms.2012.27.11.1411
DO - 10.3346/jkms.2012.27.11.1411
M3 - Article
C2 - 23166426
AN - SCOPUS:84872542959
SN - 1011-8934
VL - 27
SP - 1411
EP - 1417
JO - Journal of Korean Medical Science
JF - Journal of Korean Medical Science
IS - 11
ER -